DEREK DIROCCO

Derek DiRocco stands as a distinguished Partner at RA Capital, a prominent investment firm renowned for its strategic focus on the life science and biotechnology sectors. In his pivotal role, Mr. DiRocco is instrumental in shaping RA Capital's investment landscape, concentrating on groundbreaking opportunities within therapeutics, medical devices, and diagnostics. His expertise helps identify companies poised to make significant advancements in patient care and medical innovation.

At RA Capital, Derek DiRocco leverages his extensive scientific knowledge and strategic acumen to evaluate potential investments, guide portfolio companies, and contribute to the firm's overall success. He is deeply involved in the due diligence process, assessing the scientific merit, market potential, and operational viability of emerging biotech and medtech firms. His work ensures that RA Capital continues to back ventures with the highest potential for impact and return.

Before joining RA Capital in 2017, Mr. DiRocco honed his strategic and analytical skills as a consultant at McKinsey & Company. During his tenure at McKinsey, he provided invaluable counsel to a diverse range of pharmaceutical and medical device companies. His consulting work encompassed critical areas such as corporate strategy development, mergers and acquisitions, and commercialization strategies, equipping him with a comprehensive understanding of the life science industry's complex dynamics.

Derek DiRocco's robust educational background underpins his success in the highly specialized field of life science investing. He earned his Ph.D. in Biological Engineering from the Massachusetts Institute of Technology (MIT), a testament to his profound scientific capabilities. Prior to his doctoral studies, he completed his B.S. in Biomedical Engineering from Boston University, laying a strong foundation in the intersection of engineering and medicine. This blend of advanced scientific education and practical industry experience makes him a formidable force in identifying and supporting the next generation of life science breakthroughs. While specific individual investments are often proprietary, his focus areas consistently include companies developing novel drug therapies, innovative diagnostic tools, and advanced medical technologies that address unmet medical needs and improve patient outcomes globally.